Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran(Aarhus University Hospital), Marius Ardeleanu(Regeneron (United States)), John D. Davis(Providence College), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Michihiro Hide(Hiroshima City Asa Citizens Hospital), Joel M. Gelfand(University of Pennsylvania), Robert Bissonnette(Innovaderm (Canada)), Manoj Rajadhyaksha(Alexion Pharmaceuticals (United States)), Laurent Eckert(Sanofi (France)), Bolanle Akinlade(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Seth Forman, Andrew Blauvelt(Veterans Health Administration), Jean‐David Bouaziz(Université Paris Cité), Lisa A. Beck(University of Rochester Medicine), Weily Soong(Allergy, Asthma and Clinical Research Center), Diamant Thaçi(University of Lübeck), Marie L. A. Schuttelaar(University Medical Center Groningen), Heribert Staudinger(Sanofi (United States)), Chen Wang(Shanghai Medical College of Fudan University), Zhen Chen(The First People's Hospital of Shunde), Iftikhar Hussaın, Gianluca Pirozzi(Sanofi (United States)), Lawrence Sher(Peninsula Research), Peter Foley(The University of Melbourne), Abhijit Gadkari(Regeneron (United States)), Kristian Reich(Dermatologikum Hamburg)
Cited by 257
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k